Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

No More Deal? Novartis, Amgen Trade Lawsuits Over Aimovig Agreements

Apr 05 2019

• By Mandy Jackson

Close up golden chess pieces with blurry judge gravel and law book background.

Related Content

Deal Watch: Novartis Signs Deals In Migraine & Diabetes

Apr 24 2017

Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?

Sep 18 2018

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims

Feb 09 2018

Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches

Nov 10 2018

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA's Gottlieb

Jan 09 2019

Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs

Sep 02 2015

Novartis To Ape Aimovig's US Market Strategy In The EU As CHMP Gives Market Go-Ahead

Jun 01 2018

Related Companies

Amgen, Inc.

Novartis AG

Alder Biopharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

Allergan plc

Biohaven Pharmaceutical Holding Company Ltd.

Novartis AG

Additional Topics

Legal Issues Deals Business Strategies Commercial Neurology BioPharmaceutical

More from Legal & IP

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window